Cell therapy in ALS: An update on preclinical and clinical studies

Keyphrases

• Amyotrophic Lateral Sclerosis 100%
• Cell Therapy 100%
• Stem Cells 33%
• Clinical Trials 16%
• Mechanism of Action 16%
• Motor Neuron 16%
• Neurotoxicity 16%
• Tolerability 16%
• Skeletal muscle 16%
• Clinical Outcomes 16%
• Respiratory Failure 16%
• Promising Strategies 16%
• Optimal Growth 16%
• Progressive Neurodegeneration 16%
• Recent Advances 16%
• Neuroinflammation 16%
• Multiple Mechanisms 16%
• Clinical Investigator 16%
• Phase I Clinical Trial 16%
• Functional Improvement 16%
• Premature Death 16%
• Stem Cell Therapy 16%
• Motor Unit 16%
• Muscle Paralysis 16%
• Phase II Clinical Trial 16%
• Related Pathway 16%
• Multiple Sites 16%
• Central Compartment 16%
• Coordinated Efforts 16%
• Human Trials 16%
• Neuromuscular Impairment 16%
• Stem Cell Source 16%
• Peripheral Compartment 16%
• Growth Factor Support 16%
• Neurotrophic Support 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Clinical Study 100%
• Preclinical Study 100%
• Amyotrophic Lateral Sclerosis 100%
• Clinical Trial 50%
• Disease 33%
• Growth Factor 16%
• Tolerability 16%
• Degenerative Disease 16%
• Respiratory Failure 16%
• Excitotoxicity 16%
• Prematurity 16%
• Nervous System Inflammation 16%
• Paralysis 16%

Neuroscience

• Amyotrophic Lateral Sclerosis 100%
• Cell Therapy 100%
• Stem Cell 66%
• Neuromuscular 50%
• Neurodegenerative Disorder 16%
• Growth Factor 16%
• Excitotoxicity 16%
• Motor Neuron 16%
• Skeletal Muscle 16%
• Motor Unit 16%